Medical Information Only. Always consult your healthcare provider before enrolling in any clinical trial.
NCT03944954 · ClinicalTrials.gov registry record · Early Phase 1
Neural Mechanisms of Cannabinoid-impaired Decision-Making in Emerging Adults
A Early Phase 1 study of Substance-Related Disorders and Behavior Problem, sponsored by Michael J. Wesley, PhD.
- Completed
- Registry status
- Early Phase 1
- Development phase
- 66
- Enrollment target
- 1
- Study location
NCT03944954 is a Early Phase 1 study of Substance-Related Disorders and Behavior Problem that has completed, run by Michael J. Wesley, PhD. The registered enrollment target is 66 participants, below the 1,520-participant average among 58 other Substance-Related Disorders trials with a reported enrollment target (96% lower). The trial reports 1 study location across 1 state.
The verdict
NCT03944954, a Early Phase 1 study of Substance-Related Disorders and Behavior Problem, has completed, sponsored by Michael J. Wesley, PhD.
- COMPLETED
- Registry status
- Early Phase 1
- Development phase
- 66 participants
- Enrollment target
- 1
- Study location
Study Summary
Emerging adults are a particularly vulnerable group for experiencing the immediate and potentially lifelong negative impacts of habitual cannabis use, and trends suggest that cannabis use disorder (CUD) will soon escalate in this population. The proposed research will combine clinical pharmacology, non-invasive brain stimulation, and neuroimaging techniques to establish the brain mechanisms of cannabinoid-impaired decision-making processes in emerging adults with CUD. Results from this project will inform CUD prevention/treatment efforts in this high-risk group and address a growing public health concern.
Conditions Studied
Interventions
- DEVICE Placebo TMS Sham
- DRUG Marinol 10Mg Capsule TMS Sham
- DRUG Marinol 30Mg Capsule TMS Sham
- DEVICE Placebo TMS Real
- OTHER Marinol 10Mg Capsule TMS Real
Study Locations (1)
Kentucky
- Neurobehavioral Systems Lab of the University of Kentucky College of Medicine - Lexington
Trial Details
| Field | Value |
|---|---|
| Enrollment Target | 66 participants |
| Start Date | 2017-07-15 |
| Est. Completion | 2023-12-13 |
| Phase | Early Phase 1 |
Interested in This Trial?
Full Details on ClinicalTrials.gov ↗What the Registry Record Tells You About NCT03944954
The ClinicalTrials.gov registry entry for NCT03944954 describes a study currently listed as completed, categorized as Early Phase 1. The registered enrollment target is 66 participants, a figure that helps gauge the scale of data the investigators plan to collect, below the 1,520-participant average among 58 other Substance-Related Disorders trials with a reported enrollment target (96% lower). The listed sponsor is Michael J. Wesley, PhD, which has 2 total studies on file at ClinicalTrials.gov.
The record links to 3 conditions, with Substance-Related Disorders appearing as the primary indexed condition, and to 5 interventions - of which Placebo TMS Sham is the first listed.
NCT03944954 reports 1 study location spanning 1 distinct geographic area - top geographies include Kentucky.
Frequently Asked Questions
What is clinical trial NCT03944954 about?
NCT03944954 is a clinical study titled "Neural Mechanisms of Cannabinoid-impaired Decision-Making in Emerging Adults". Emerging adults are a particularly vulnerable group for experiencing the immediate and potentially lifelong negative impacts of habitual cannabis use, and trends suggest that cannabis use disorder (CUD) will soon escalate in this population. The proposed research will combine clinical pharmacology, ...
What is the current status of trial NCT03944954?
This trial is currently completed. It is a Early Phase 1 study. The enrollment target is 66 participants. The study started on 2017-07-15. Estimated completion is 2023-12-13.
What conditions does trial NCT03944954 study?
This clinical trial studies the following conditions: Substance-Related Disorders, Behavior Problem, Neurosciences.
What interventions are being tested in trial NCT03944954?
The interventions under investigation include: Placebo TMS Sham (DEVICE), Marinol 10Mg Capsule TMS Sham (DRUG), Marinol 30Mg Capsule TMS Sham (DRUG), Placebo TMS Real (DEVICE), Marinol 10Mg Capsule TMS Real (OTHER).
Who is sponsoring clinical trial NCT03944954?
This trial is sponsored by Michael J. Wesley, PhD, which has 2 total clinical trials registered on ClinicalTrials.gov.
Where is trial NCT03944954 being conducted?
This trial has 1 study location across Kentucky. Contact the study sites directly through ClinicalTrials.gov for enrollment availability.
Learn More About Clinical Trials
Similar trials for Substance-Related Disorders
Matched on the same primary condition, ranked to surface studies in the same phase first, then by recruiting status, no relevance scoring or editorial curation.
-
Phase II: Scalable Digital Delivery of CRAFT Training for Professionals to Maximize Treatment Rates of OUD in Families
RECRUITING · NA
-
Disrupting SRFOH to Improve Substance Use and Mental Health Outcomes for Parents in Rural Regions
RECRUITING · NA
-
Feasibility of the 5-Step Method in the U.S.
RECRUITING · NA
-
SMART-r: Substance Monitoring and Active Relapse Tracking Repository
RECRUITING
-
Whole Health in VA Mental Health: Omnis Salutis
RECRUITING · NA
-
Expression of Stress Markers During Meth Treatment (EXPRESS+)
RECRUITING · NA
Explore more on PlainTrial
Read our methodology - how this data is sourced, computed, and verified.
Related
Every figure on PlainTrial is rendered directly from the ClinicalTrials.gov registry, no number is typed in by an editor. This page mirrors this trial's own ClinicalTrials.gov registry record, live from the dataset. See our editorial standards & corrections policy, the methodology behind these numbers, or report a data error.